Newsroom | Press Releases and Feature Articles

May 23, 2019

Glytec Goes Global, With Six New International Patent Allowances

The digital therapeutics pioneer is expanding its intellectual property footprint beyond the U.S., gaining worldwide protections for its proprietary diabetes therapy management solutions.

The rise in diabetes is truly a global phenomenon. The World Health Organization has been vocal about the estimated 422 million people living with diabetes, saying: “the prevalence of diabetes is steadily increasing everywhere” and “diabetes and its complications impact harshly on the finances of individuals and their families, and the economies of nations.” Glytec recognizes that optimizing diabetes medications and making insulin a more effective and accessible option stands to benefit not only those living in the U.S, but people around the world. To that end, the company is growing its intellectually property portfolio on an international scale.

May 16, 2019

Glytec Awarded Patent Allowance for Virtual Insulin Titration in Concert with CGM, Smart Pens and Other Diabetes Technologies

The company’s growing intellectual property portfolio attests to its leadership position in diabetes medication optimization in an era of data-driven care.

Glytec, the pioneer of digital therapeutics, has been awarded another patent allowance by the United States Patent and Trademark Office (USPTO). The latest allowance references interactions between the company’s software-as-a-medical-device platform for insulin titration and multiple connected diabetes technologies, including continuous glucose monitoring (CGM) systems, smart insulin pens and insulin pumps.

May 14, 2019

Glytec and Onduo to Deliver Webinar on Virtual Diabetes Care in Partnership with HIMSS

The May 30, 2019 webinar will explore the keys to augmenting traditional brick-and-mortar care with virtual care for people with diabetes.

Managing the care of people with diabetes is costly and time intensive, especially for our nation’s primary care providers who shoulder 80% of that responsibility. Virtual care programs have the potential to fill critical gaps and meet increasing demands, but can they produce real results?

April 30, 2019

Metro Health – University of Michigan Health to Use Glytec’s Software for Inpatient Diabetes Care

The Wyoming, Michigan-based healthcare organization will partner with Glytec to provide patients an integrated model of technology-enabled glycemic management.

Known for high-quality, personalized care and award-winning services, Metro Health – University of Michigan Health is taking inpatient diabetes management to the next level. With a decades-long focus on ensuring glucose control is a top priority, the healthcare organization has selected Glytec’s eGlycemic Management System® (eGMS®) to advance the standardization of best practice. The software-as-a-medical-device eGMS® platform is both patented and FDA cleared.

April 9, 2019

Glytec Receives Another Patent Allowance for Therapy Advisor®

The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications.

The United States Patent and Trademark Office has granted Glytec another patent allowance for systems and methods related to a product registered under the brand name, Therapy Advisor®. Currently under development, the new product will extend the company’s core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.

March 27, 2019

DarioHealth Partners with Glytec on Outpatient Diabetes Management

The Dario® Blood Glucose Monitoring System will be made available to hospitals and health systems using Glytec’s virtual insulin titration service for outpatients with diabetes.

Global digital therapeutics innovator, DarioHealth Corp. (Nasdaq: DRIO), today announced a joint marketing agreement with Glytec, the market leader and pioneer of insulin titration solutions for use across the full continuum of care. The agreement allows DarioHealth’s smart glucose meter (part of the Dario Blood Glucose Monitoring System) to transmit information to Glytec’s Glucommander™ Outpatient software-as-a-medical-device.

March 12, 2019

Computerized Systems for Managing Glucose Will Become Standard of Care in Hospitals, Anticipates Dr. Bruce Bode

A presentation at ATTD 2019 by renowned diabetologist and researcher, Dr. Bruce Bode, showcased superior clinical and financial outcomes with Glytec’s eGlycemic Management System® versus usual care across multiple studies.

In conclusion to his plenary session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), Dr. Bruce Bode delivered a call-to-action to an audience of his peers, espousing they do what is necessary to normalize glucose for all hospitalized patients (emphasis on ALL). He stressed that rates of hypoglycemia remain unacceptably high and use of sliding scale insulin continues to be prevalent despite abundant evidence denouncing it as unsafe and lacking efficacy. “Patients deserve better,” said Bode. With a clear focus on the solution to a decades-long problem of poor glucose control in hospitals, Bode described in detail the advantages of computerized decision support, highlighting data from multiple studies of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) that demonstrate consistently superior outcomes versus usual care, including significant reductions in hypoglycemia, 30-day readmissions and lengths of stay.

January 15, 2019

At a Cost of $10,405 Per Patient Stay, Hypoglycemia in The Hospital Cannot Be Ignored

A diabetes webinar hosted by the American Hospital Association and sponsored by Glytec showcased why hypoglycemia prevention is imperative to the safety of patients and to the economics of healthcare delivery.

Featured speakers, Dr. Richard Pratley of Florida Hospital System and Dr. Steven Edelman of UC San Diego Health, recently delivered a unified message to several hundred senior healthcare professionals attending an American Hospital Association webinar: Hypoglycemia [low blood sugar] in the hospital is a major patient safety risk with significant clinical and financial implications. A case study presented by Pratley further revealed that insulin-managed patients who experience severe hypoglycemia, or blood sugar less than 40 mg/dL, have longer stays, higher readmission and mortality rates, and an overall cost of care $10,405 greater than patients whose blood sugar remains in the normal range.

December 18, 2018

Paula LeClair Joins Glytec as Executive Director and General Manager, Outpatient

She joins Glytec in a role that will tap her skills and experience leading operations and commercialization of emerging diabetes technologies and services.

Glytec, the pioneer of digital therapeutics and leader in insulin optimization, welcomes Paula LeClair as Executive Director and General Manager, Outpatient. In the diabetes industry, LeClair’s name is synonymous with transformation and innovation.

November 28, 2018

Glytec to Host Webinar in Partnership with American Hospital Association: Improving the Quality and Cost of Diabetes Care

The December 13, 2018 webinar is open to hospital and health system personnel nationwide and will feature Dr. Richard E. Pratley of Florida Hospital System and Dr. Steven V. Edelman of UC San Diego Health.

The population of hospitalized patients with diabetes is on the rise, as is the cost and intensity of their care. Glytec is partnering with the American Hospital Association to deliver a webinar that brings greater attention and awareness to reducing risks and improving safety for patients with diabetes.

Page 3 of 13

Page 3 of 13
←
1
...
2
3
4
...
13
→